219 related articles for article (PubMed ID: 34030125)
21. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
22. Mammary analogue secretory carcinoma: A challenging case arising in a young man with radiation exposure.
Sivasubramaniam P; Tiegs-Heiden CA; Geiersbach KB; Hagen CE; Sturgis CD; Thangaiah JJ; Hartley CP
Ann Diagn Pathol; 2022 Apr; 57():151862. PubMed ID: 34953444
[TBL] [Abstract][Full Text] [Related]
23. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
[TBL] [Abstract][Full Text] [Related]
24. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
[TBL] [Abstract][Full Text] [Related]
25. Primary Mammary Analog Secretory Carcinoma (MASC) of the Vulva With ETV6-NTRK3 Fusion: A Case Report.
Nguyen JK; Bridge JA; Joshi C; McKenney JK
Int J Gynecol Pathol; 2019 May; 38(3):283-287. PubMed ID: 29672325
[TBL] [Abstract][Full Text] [Related]
26. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.
Skálová A; Vanecek T; Sima R; Laco J; Weinreb I; Perez-Ordonez B; Starek I; Geierova M; Simpson RH; Passador-Santos F; Ryska A; Leivo I; Kinkor Z; Michal M
Am J Surg Pathol; 2010 May; 34(5):599-608. PubMed ID: 20410810
[TBL] [Abstract][Full Text] [Related]
27. Secretory Carcinoma of the Skin Harboring ETV6 Gene Fusions: A Cutaneous Analogue to Secretory Carcinomas of the Breast and Salivary Glands.
Bishop JA; Taube JM; Su A; Binder SW; Kazakov DV; Michal M; Westra WH
Am J Surg Pathol; 2017 Jan; 41(1):62-66. PubMed ID: 27631515
[TBL] [Abstract][Full Text] [Related]
28. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
29. [Clinicopathologic features of mammary analogue secretory carcinoma of salivary glands].
Zhang XP; Ni H; Wang X; Chen H; Shi SS; Yu B; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):34-37. PubMed ID: 28072974
[No Abstract] [Full Text] [Related]
30. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
31. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion.
Ito Y; Ishibashi K; Masaki A; Fujii K; Fujiyoshi Y; Hattori H; Kawakita D; Matsumoto M; Miyabe S; Shimozato K; Nagao T; Inagaki H
Am J Surg Pathol; 2015 May; 39(5):602-10. PubMed ID: 25651470
[TBL] [Abstract][Full Text] [Related]
32. Concurrent Identification of Novel EGFR-SEPT14 Fusion and ETV6-RET Fusion in Secretory Carcinoma of the Salivary Gland.
Black M; Liu CZ; Onozato M; Iafrate AJ; Darvishian F; Jour G; Cotzia P
Head Neck Pathol; 2020 Sep; 14(3):817-821. PubMed ID: 31502214
[TBL] [Abstract][Full Text] [Related]
33. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers.
Urano M; Nagao T; Miyabe S; Ishibashi K; Higuchi K; Kuroda M
Hum Pathol; 2015 Jan; 46(1):94-103. PubMed ID: 25456394
[TBL] [Abstract][Full Text] [Related]
34. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
35. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
O'Reilly EM; Hechtman JF
Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
[TBL] [Abstract][Full Text] [Related]
36. NTRK fusions in lung cancer: From biology to therapy.
Harada G; Santini FC; Wilhelm C; Drilon A
Lung Cancer; 2021 Nov; 161():108-113. PubMed ID: 34563714
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
Boon E; Valstar MH; van der Graaf WTA; Bloemena E; Willems SM; Meeuwis CA; Slootweg PJ; Smit LA; Merkx MAW; Takes RP; Kaanders JHAM; Groenen PJTA; Flucke UE; van Herpen CML
Oral Oncol; 2018 Jul; 82():29-33. PubMed ID: 29909898
[TBL] [Abstract][Full Text] [Related]
38. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
[TBL] [Abstract][Full Text] [Related]
39. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
Blauel ER; Laetsch TW
Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
[TBL] [Abstract][Full Text] [Related]
40. Mammary Analogue Secretory Carcinoma of Minor Salivary Glands: A Rare Case Series and Review of the Literature.
Roy S; Saluja K; Zhu H; Zhao B
Ann Clin Lab Sci; 2018 Jan; 48(1):94-99. PubMed ID: 29531003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
